Gritstone Oncology Inc
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for tre… Read more
Gritstone Oncology Inc (GRTS) - Total Liabilities
Latest total liabilities as of June 2024: $120.35 Million USD
Based on the latest financial reports, Gritstone Oncology Inc (GRTS) has total liabilities worth $120.35 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Gritstone Oncology Inc - Total Liabilities Trend (2016–2023)
This chart illustrates how Gritstone Oncology Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Gritstone Oncology Inc Competitors by Total Liabilities
The table below lists competitors of Gritstone Oncology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Korporacja Gospodarcza efekt S.A
WAR:EFK
|
Poland | zł69.98 Million |
|
Mountain Boy Minerals Ltd
OTCQB:MBYMF
|
USA | $3.76 Million |
|
Prosper Gold Corp
OTCQX:PGXFF
|
USA | $206.33K |
|
Jeffs' Brands Ltd
NASDAQ:JFBR
|
USA | $14.82 Million |
|
JSS Real Estate SOCIMI SA
MC:YJSS
|
Spain | €291.53 Million |
|
CEKD Bhd
KLSE:0238
|
Malaysia | RM8.24 Million |
Liability Composition Analysis (2016–2023)
This chart breaks down Gritstone Oncology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.84 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gritstone Oncology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gritstone Oncology Inc (2016–2023)
The table below shows the annual total liabilities of Gritstone Oncology Inc from 2016 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $125.92 Million | +79.95% |
| 2022-12-31 | $69.97 Million | +12.82% |
| 2021-12-31 | $62.02 Million | +13.12% |
| 2020-12-31 | $54.83 Million | +9.56% |
| 2019-12-31 | $50.05 Million | +23.76% |
| 2018-12-31 | $40.44 Million | +102.00% |
| 2017-12-31 | $20.02 Million | +323.03% |
| 2016-12-31 | $4.73 Million | -- |